Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Myeloma patients who relapse after prior treatment with bortezomib and lenalidomide have survival of less than 1 year. Recently, a randomized study of Pomalidomide and dexamethasone conducted in

cancer
bilateral oophorectomy
hysterectomy
neutrophil count
maintenance therapy
  • 34 views
  • 31 Jan, 2022
  • 1 location
Pomalidomide Treatment in Patients With Kaposi Sarcoma

This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the

  • 0 views
  • 10 Mar, 2022
  • 2 locations
Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)

This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or

blood transfusion
pomalyst
parenteral infusion
iron
epistaxis
  • 11 views
  • 06 Apr, 2022
  • 10 locations
Pomalidomide Ixazomib and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in the study. After the first 6 patients will have finished the first …

alkylating agents
cell transplantation
neutrophil count
pomalidomide
bortezomib
  • 2 views
  • 18 Sep, 2021
  • 18 locations
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant

neutrophil count
daratumumab
ejection fraction
tumor cells
withdrawn
  • 2 views
  • 03 Feb, 2022
  • 1 location
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

and assigned into one of the following treatment arms: Arm 1: Selinexor + pomalidomide + dexamethasone (SPd) Arm 2: Selinexor + daratumumab + dexamethasone (SDd) Arm 3: Selinexor

  • 0 views
  • 25 Mar, 2022
  • 1 location
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib

cancer
measurable disease
pomalidomide
bortezomib
refractory multiple myeloma
  • 10 views
  • 11 Mar, 2022
  • 111 locations
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive

proteasome inhibitor
measurable disease
pomalidomide
refractory multiple myeloma
lenalidomide
  • 99 views
  • 30 Apr, 2022
  • 158 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)

pomalidomide
bortezomib
monoclonal protein
serum proteins
measurable disease
  • 57 views
  • 19 Apr, 2022
  • 18 locations
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)

benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment

measurable disease
refractory multiple myeloma
lenalidomide
dexamethasone
  • 0 views
  • 14 May, 2022
  • 12 locations